Results from a 12-month, open-label safety study in patients with migraine1
In a 12-month, open-label safety study of patients with episodic or chronic migraine with 4 or more migraine headache days (MHDs) per month1
Meet a patient with episodic migrainea
- 4 or more unpredictable headache days per month
- Has tried therapeutic doses of 2 standard-of care generic preventives
- May now be only relying on her acute treatments
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.